New Data Reinforce Iptacopan's Role in Transforming PNH Care With Hemoglobin, QOL Gains
December 6th 2024Promising topline results from a phase 3B study show the efficacy and quality of life (QOL) improvements of iptacopan (Fabhalta) as a twice-daily oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who transitioned from anti-C5 therapies.
Read More
Acoramidis Sustains Benefits in Patients With ATTR-CM in Open-Label Extension Study
December 6th 2024Data presented at the 2024 American Heart Association (AHA) Scientific Sessions showed that continuous treatment with acoramidis (Attruby; BridgeBio Pharma) significantly reduced the risk of all-cause mortality (ACM) and cardiovascular-related hospitalizations (CVH) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
Read More
ICYMI: Highlights From ERS Congress 2024
December 6th 2024Top coverage from the European Respiratory Society (ERS) Congress 2024 spanned various topics, including artificial intelligence–powered robots transforming respiratory care and late-breaking findings on an epilepsy drug showing promise for treating obstructive sleep apnea.
Read More
Slow, Steady Advances: Noninvasive Diagnosis of PH in ILD Populations
December 5th 2024Many roadblocks exist to detecting and assessing pulmonary hypertension (PH) in patients with interstitial lung disease (ILD), but creative thinking and artificial intelligence (AI) may soon help improve the landscape.
Read More
Initiating PrEP Through the Emergency Department Has Pros, Cons to Improving Uptake
December 5th 2024A qualitative study spoke to emergency department and HIV clinic staff to evaluate the feasibility of initiating pre-exposure prophylaxis (PrEP) in patients visiting the emergency department.
Read More
Optimizing Outcomes in NSCLC With Precision Medicine and Teamwork
December 4th 2024Divya Gupta, MD, assistant professor at the Northwestern University Feinberg School of Medicine, emphasized the transformative role of biomarker-driven therapies in advancing non–small cell lung cancer (NSCLC) treatment and highlighted the critical importance of multidisciplinary collaboration.
Watch